To include your compound in the COVID-19 Resource Center, submit it here.

Acceleron, Celgene amend sotatercept deal for pulmonary hypertension

Acceleron Pharma Inc. (NASDAQ:XLRN) gained worldwide rights to develop and commercialize sotatercept to treat pulmonary hypertension, amending a deal with partner Celgene Corp.(NASDAQ:CELG). Acceleron expects

Read the full 252 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE